SCHEMBL5497323

SCHEMBL5497323

Cc1ccc(-c2nc3ccccc3[nH]2)cc1-c1ccc2nc(NCCCN3CCOCC3)ncc2c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RIPK1 Q13546 1/20 0.58
RIPK3 Q9Y572 1/20 0.58
LCK P06239 8/20 0.56
KDR P35968 8/20 0.56
MAPK14 Q16539 8/20 0.56
JAK3 P52333 4/20 0.56
MAPK9 P45984 2/20 0.56
MAPK10 P53779 2/20 0.56
KIT P10721 1/20 0.56
SRC P12931 2/20 0.51
TYK2 P29597 1/20 0.51
SYK P43405 1/20 0.51
MAPK8 P45983 1/20 0.51
BTK Q06187 1/20 0.51
ALDH1A1 P00352 4/20 0.50
KDM4E B2RXH2 4/20 0.50
MAPK1 P28482 2/20 0.50
POLB P06746 1/20 0.50
DUSP3 P51452 1/20 0.50
PTPN5 P54829 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5493428 0.89 LCK (0.58) RIPK1RIPK3LCKKDRMAPK14
SCHEMBL5494563 0.85 RIPK1 (0.63) RIPK1RIPK3LCKKDRMAPK14
SCHEMBL5502267 0.80 RIPK1 (0.70) RIPK1RIPK3LCKKDRMAPK14
SCHEMBL5497210 0.79 MAPK14 (0.72) RIPK1RIPK3LCKKDRMAPK14
SCHEMBL5488819 0.79 SRC (0.60) RIPK1RIPK3LCKKDRMAPK14
SCHEMBL5497244 0.78 LCK (0.54) LCKKDRMAPK14JAK3ALDH1A1
SCHEMBL5497434 0.77 LCK (0.56) RIPK1RIPK3LCKKDRMAPK14
SCHEMBL5496169 0.77 MAPK14 (0.91) RIPK1RIPK3LCKKDRMAPK14
SCHEMBL5497137 0.76 RIPK1 (0.68) RIPK1RIPK3LCKKDRMAPK14
SCHEMBL20516543 0.75 RIPK2 (0.65) RIPK1RIPK3LCKKDRMAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1836174-B2 ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS AMGEN INC (US) 2019-10-02 EP claimed
EP-1836174-B1 ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS AMGEN INC (US) 2013-02-27 EP claimed
EP-1836174-A2 ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS AMGEN INC. (US) 2007-09-26 EP claimed
US-20070054916-A1 Aryl nitrogen-containing bicyclic compounds and methods of use AMGEN INC. 2007-03-08 US claimed
WO-2006039718-A2 ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS AMGEN INC (US) 2006-04-13 WO claimed
US-20070054916-A1 Aryl nitrogen-containing bicyclic compounds and methods of use AMGEN INC. 2007-03-08 US disclosed
US-20070054916-A1 Aryl nitrogen-containing bicyclic compounds and methods of use AMGEN INC. 2007-03-08 US disclosed
US-20070054916-A1 Aryl nitrogen-containing bicyclic compounds and methods of use AMGEN INC. 2007-03-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070054916-A1 Aryl nitrogen-containing bicyclic compounds and methods of use MAP3K1, MAP3K5, MAP3K2 RIPK1 653/4885RIPK3 494/4885LCK 106/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.